Roche names Pao head of drugs research and early development

ZURICH (Reuters) – Swiss drugmaker Roche named U.S. cancer expert William Pao head of its Pharma Research and Early Development (pRED) business after John Reed decided to leave for what it called personal reasons.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply